BriaCell (BCTX) Therapeutics and its majority owned subsidiary, BriaPro Therapeutics, announce that BriaPro is developing novel multivalent agents for cancer treatment. BriaPro has filed a provisional patent application for the underlying platform referred to as “TILsRx”. “Our advanced multivalent technology provides us with a platform to quickly expand our proprietary pipeline of novel immuno-oncology programs in BriaPro in a cost-effective manner,” stated Dr. William Williams, BriaPro and BriaCell President & CEO. “We anticipate that the multivalent approach will have activity against multiple types of cancers and may also synergize with BriaCell’s cell-based cancer vaccine programs.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCTX:
- BriaCell to Present Key Clinical Data at ESMO 2025
- Three new option listings and ten option delistings on July 21st
- BriaCell Therapeutics Secures $15 Million in Public Offering
- BriaCell sinks 61% to 79c after pricing 12M unit offering at $1.25
- BriaCell says $15M unit offering prices at $1.25 per unit